Ownership
Private
Employees
~10
Therapeutic Areas
PsychiatryCardiovascularImmunologyWomen's HealthOncologyInfectious Diseases
Stage
Phase 3
Modalities
Lateral flow assaysPoint-of-care diagnosticsMolecular diagnosticsAntibody-based immunotherapy

Azure Biotech General Information

Azure Biotech, Inc. is conducting clinical trials for Lasofoxifene Tartrate, with the highest phase being Phase 3 for ER-positive/HER2-negative/ESR1-mutated breast cancer. A Phase 1/2 trial for AZU-101 in postmenopausal women is planned to start in May 2024.

Contact Information

Website
Primary Industry
[ "Diagnostics", "Biotech" ]
Corporate Office
Oregon, Oregon
United States

Drug Pipeline

lasofoxifene tartrate
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Azure Biotech's pipeline data

Book a demo

Key Partnerships

Sermonix Pharmaceuticals LLC, Pfizer Inc.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Azure Biotech Funding

Deal TypeDateAmountStatusStage
Later Stage VCJan 7, 2015$355.0KCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Azure Biotech's complete valuation and funding history, request access »